Form F-3
Filed with ASX · · 47 pages · English
On 6ix: 6ix.com/news/form-f-3-1
Melbourne, Australia, January 15, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company wishes to advise that it has filed its Registration Statement on Form F-3 with the US Securities and Exchange Commission. A copy of the Form F-3 has been appended to this announcement. ---End--- COMPANY CONTACT: USA INVESTOR RELATIONS: AUS INVESTOR RELATIONS: Gary S.
Earlier from Immuron
- Immuron Receives $1.19M R&D Tax Concession Refund
- IMC Appoints Experienced US Based Biotech Executive as CEO
- NASH clinical trial presentation & continued revenue growth
- US DoD Report Travelan Protects Against Shigella in Primates
- Immuron Reports Record Revenue
Later from Immuron
- Travelan FY19 Update and Expansion into North America
- Company Update on CDI Clinical Trial and New Strategic Focus
- Immuron Aims to Secure FDA Approval for IMM-124E
- Immuron sales surge by 66% in the Third Quarter of FY19
- Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron